Outset Medical Awarded VA Contract Aimed at Improving Dialysis Care for Veterans

Outset Medical, Inc. (Nasdaq: OM) (“Outset”) announced today that the Strategic Acquisition Center (SAC) Office of Procurement, Department of Veterans Affairs awarded a national contract that enables the company’s Tablo® Hemodialysis System to be sold into the 106 VA hospitals in the U.S.

VA medical facilities across the U.S. provide dialysis care for 35,000 veterans. While Tablo is already deployed in some of those facilities, the new five-year contract will enable VA centers to acquire consoles to send veterans home and expand usage in the acute setting. The award provides for an indefinite quantity of services and goods during the Indefinite Delivery Indefinite Quantity (IDIQ) Award Contract. As part of one of the three centralized contracting entities within the VA, the SAC has been tasked to create superior procurement solutions that deliver on the VA’s promise to veterans.

“Our honored veterans deserve to have the most advanced dialysis care possible, and it is our great privilege to support them through the SAC contract for hemodialysis care,” said Leslie Trigg, Chair and Chief Executive Officer of Outset Medical. “This partnership with the VA will further our mission to bring a technology-enabled, patient-centered approach to dialysis both in the acute and home setting.”

Outset Medical offers the Tablo Hemodialysis System for kidney patients, which is a first-of-its-kind enterprise solution, FDA-cleared for use across the entire continuum of care — from hospital to home. A connected and intelligent device, Tablo has two-way communication with the cloud, which allows treatment data to be sent electronically and enables physicians to remotely monitor patients so that they feel connected to their medical team while being comfortable at home.

Outset Medical, through SDV Medical, was awarded the contract opportunity for SLED, HHD integrated HD/water purification and IHD integrated HD/water purification dialysis:

  • SLED, or Slow Low Efficiency Dialysis, with Tablo allows for the ability to offer adaptive dialysis specific to a patient’s needs. Incumbent dialysis machines provide either a continuous 24-hour treatment or a short (3-4 hour) treatment, but lack the clinical flexibility to offer treatment durations in between. By contrast, Tablo offers clinicians the flexibility to align treatment time to the patient’s clinical needs.
  • HHD, or home hemodialysis, allows the patient to perform dialysis treatments in their own home, safely and efficiently, using Tablo, which requires only a standard electrical outlet and tap water to operate.
  • IHD, or intermittent hemodialysis, allows for traditional dialysis treatment over a 3 to 4-hour period in a chronic or acute setting.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version